Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver
diseases in developed countries, and its prevalence and incidence are rapidly increasing …

Recently, some preclinical and clinical studies have demonstrated the ability of brown
seaweeds in reducing the risk factors for metabolic syndrome. Here, we analyzed the …

Non-alcoholic fatty liver disease (NAFLD) is a common and prevalent disorder affecting 25
percent of the adults in the United States and 32 percent of adults globally. It is one of the …

Abstract Endoplasmic Reticulum Stress (ERS) is a key factor in the development of Non-
Alcoholic Fatty Liver Disease (NAFLD) in diabetes. The current study aimed to examine the …

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disorder
worldwide. It comprises simple steatosis and non-alcoholic steatohepatitis (NASH), which …

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-
alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the …

Context The management of solid-organ transplantation is rapidly evolving, and
posttransplant diabetes mellitus (PTDM), which is increasingly common, is a barrier to …

Background NAFLD and NASH are emerging as primary causes of chronic liver disease,
indicating a need for an effective treatment. Mutaflor® probiotic, a microbial treatment of …

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease in the
world and represents a clinical-histopathologic entity where the steatosis component may …

Background and Objectives: Non-alcoholic steatohepatitis (NASH) has become the leading
indication for liver transplantation in many countries, with a growing rate in the Western …